FDA OKs Pembrolizumab Combo Therapy for Advanced Renal Cell Carcinoma

Pembrolizumab (Keytruda, Merck) has received FDA approval as a first-line treatment in combination with axitinib (Inlyta) for patients with advanced renal cell carcinoma (RCC), making it the first indication for pembrolizumab in this patient population, according to a press release.
 
The approval is based on data from the KEYNOTE-426 clinical trial, which evaluated pembrolizumab in combination with axitinib in 861 patients who had not received systemic therapy for advanced RCC.
 
For the trial, patients were randomized to receive either pembrolizumab 200 mg intravenously every 3 weeks up to 24 months with axitinib 5 mg orally, twice daily, or sunitinib 50 mg orally, once daily for 4 weeks and then off treatment for 2 weeks.
 
Key data from the study showed:
  • Pembrolizumab plus axitinib reduced the risk of death by 47% compared with sunitinib [HR=0.69 [95% Cl, 0.57-0.85]; p=0.0001].
  • With a median follow-up of 12.8 months, overall survival (OS) was significantly improved in patients who received the combination treatment compared with sunitinib [HR=0.53 [95% Cl, 0.38=0.74]; p<0.0001].
  • Estimated 12-month OS rates were 90% [95% Cl, 86-92] with the combination treatment versus 78% [95% Cl, 74-82] with sunitinib.
  • Median progression-free survival (PFS) was 15.1 months [95% Cl, 12.6-17.7] in patients receiving the pembrolizumab plus axitinib combination versus 11.1 months [95% Cl, 8.7-12.5] with sunitinib.
  • The overall response rate (ORR) was 59% for patients who received pembrolizumab plus axitinib [95% CI, 54-64] and 36% for those who received sunitinib [95% Cl, 31-40] [p<0.0001].
Consistent results were observed across pre-specified subgroups, IMDC risk categories, and PD-L1 tumor expression status, according to the study.
 
“Given the aggressive nature of the disease, many patients with advanced renal cell carcinoma need additional treatment options that can help improve survival outcomes,” Brian Rini, MD, medical oncologist at Cleveland Clinic Cancer Center and professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, said in a statement. “Pembrolizumab in combination with axitinib offers an important new therapeutic option for physicians to consider when approaching initial treatment for patients newly diagnosed with advanced renal cell carcinoma.”
 
According to Merck, pembrolizumab is the first anti-PD-1 therapy approved by the FDA as part of a combination regimen that significantly improved OS, PFS, and ORR versus sunitinib in patients with advanced RCC.
 
Reference
 
FDA Approves Merck’s Keytruda (pembrolizumab) in Combination With Inlyta (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) [news release]. Merck. https://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-combination-inlyt. Accessed April 22, 2019.



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.
Colon cancer may spread to other parts of the body before original tumors are clinically detectable.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$